| Source publication date | (medically reviewed) |
|---|---|
| Reported on Testosterone Science | |
| Outlet type | Testosterone and hormone clinic or telehealth website |
| Population | Men |
| Source | Numan |
| URL | numan.com/low-testosterone/treatment/pros-and-cons-of-trt (opens in a new tab) |
Specific Claim Evaluated
A study of over 6,300 patients showed a mild protective effect of testosterone therapy on the heart.
Primary Research Supporting or Contradicting the Claim
The cited Medicare cohort of 6,355 men found that intramuscular testosterone was not associated with an increased risk of myocardial infarction overall, with a reduced risk only in the highest-risk quartile (Baillargeon et al., 2014). In TRAVERSE, testosterone was noninferior to placebo for major adverse cardiac events, with more atrial fibrillation and pulmonary embolism (Lincoff et al., 2023).
Corrected Evidence-Based Interpretation
Observational data and a large randomized trial show no increase in major cardiovascular events with testosterone in men with hypogonadism, but no randomized evidence shows cardiovascular protection.
Rationale for Grade
The page presents a subgroup finding from an observational cohort as a general protective effect and does not mention the randomized trial that tested cardiovascular outcomes. This is selective citation that reverses the meaning of the primary result.
References
- Baillargeon J, Urban RJ, Kuo YF, Ottenbacher KJ, Raji MA, Du F, Lin YL, Goodwin JS. Risk of myocardial infarction in older men receiving testosterone therapy. Ann Pharmacother. 2014;48(9):1138-1144. PMID
Supporting excerpt: "receipt of testosterone therapy was not associated with an increased risk of MI" - Lincoff AM, Bhasin S, Flevaris P, Mitchell LM, Basaria S, Boden WE, Cunningham GR, Granger CB, Khera M, Thompson IM, et al. Cardiovascular safety of testosterone-replacement therapy. N Engl J Med. 2023;389(2):107-117. PMID
Supporting excerpt: "noninferior to placebo with respect to the incidence of major adverse cardiac events"